RxDoctor Payments Data

Glorymardy Cruz

Family · Kingston, PANPI 1124786041

Payments from drug & device makers

$2,923in general payments, 2019–2025

Across 145 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$905
  • AstraZeneca$347
  • Teva Pharmaceuticals USA, Inc.$276
  • Lilly USA, LLC$126
  • Exact Sciences$125
  • GSK$124
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,923 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$128,922
JardianceEmpagliflozin205$61,475
TradjentaLinagliptin157$40,861
XifaxanRifaximin17$29,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$27,165
BriviactBrivaracetam16$18,446
OzempicSemaglutide16$16,894
TrulicityDulaglutide16$16,050
CreonLipase/Protease/Amylase11$14,629
FarxigaDapagliflozin Propanediol35$10,787
RestasisCyclosporine18$10,087
MyrbetriqMirabegron26$7,942
JanuviaSitagliptin Phosphate26$7,391
Potassium Chloride215$5,888
Budesonide41$5,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$128,922423 claims
Boehringer IngelheimJardiance, Tradjenta$91$102,336362 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$124$33,88375 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$29,34017 claims
AbbVieCreon, Restasis$30$24,71729 claims
Novo NordiskOzempic, Novolog$905$20,19657 claims
Lilly USA, LLCTrulicity, Humalog$126$18,55550 claims
UCB, Inc.Briviact$50$18,44616 claims
AstraZenecaFarxiga$347$10,78735 claims
Sanofi-aventis U.S. LLCLantus$28$4,78367 claims
Johnson & JohnsonXarelto$20$4,43415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →